Clinical Challenges in the Patient With Multiply Relapsed Myeloma

35
Clinical Challenges in the Patient With Multiply Relapsed Myeloma

description

Clinical Challenges in the Patient With Multiply Relapsed Myeloma. How would you approach this patient? As he was progressing on a bortezomib-based regimen, consider the pomalidomide/dexamethasone combination. Relapsed/Refractory MM New Proteasome Inhibitors . - PowerPoint PPT Presentation

Transcript of Clinical Challenges in the Patient With Multiply Relapsed Myeloma

Page 1: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

Clinical Challenges in the Patient With Multiply Relapsed Myeloma

Page 2: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 3: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 4: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 5: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 6: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 7: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

How would you approach this patient?

As he was progressing on a bortezomib-based regimen, consider the

pomalidomide/dexamethasone combination.

Page 8: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 9: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

Relapsed/Refractory MMNew Proteasome Inhibitors

Page 10: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 11: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 12: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 13: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 14: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

Relapsed/Refractory MMHDAC Inhibitors

Page 15: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 16: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 17: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 18: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

Relapsed/Refractory MMAntibodies

Page 19: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 20: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 21: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 22: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 23: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 24: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 25: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

Relapsed/Refractory MMChallenges Ahead

Page 26: Clinical Challenges in the Patient With Multiply Relapsed Myeloma
Page 27: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

Abbreviations

Page 28: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

Abbreviations (cont)

Page 29: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

References

Page 30: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

References (cont)

Page 31: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

References (cont)

Page 32: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

References (cont)

Page 33: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

References (cont)

Page 34: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

References (cont)

Page 35: Clinical Challenges in the Patient With Multiply Relapsed Myeloma

References (cont)